April 26, 2012 ·
Leave a comment
April 26, 2012 (CHAPEL HILL, NC) Thought Leader Select, a Chapel Hill, NC-based consulting firm serving the biopharmaceutical, medical device, and diagnostics industries, announces the commencement of an inter-disciplinary infectious disease engagement with a top 10 global biopharmaceutical company.
The biopharmaceutical company, part of a select group of global leaders in drug development for the treatment of infectious diseases, approached Thought Leader Select for support with its development pipeline across the Canadian market. To meet the combined strategic needs of the company’s emerging pipeline in treating conditions like HIV and Hepatitis-C, Thought Leader Select will deploy its in-house research group for a multi-disciplinary assessment of the key opinion leader community in infectious diseases.
Known for the versatility of applications for its in-house research, Thought Leader Select’s research group will analyze the skills and experience of leading specialists in the following areas:
For the first wave of the assessment, the Thought Leader Select research group will identify 50 physicians appropriate for compliant engagement in support of drug development for infectious diseases, across multiple Canadian provinces.
In the second phase of the assessment, Thought Leader Select’s in-house research group will engage in its exclusive, validated methodology of deep profiling, delivering objective assessments of the skills and experience of key opinion leaders across 14 areas where health care professionals define themselves as thought leaders, ... read more »
June 29, 2010 ·
Leave a comment
During a recent client feedback survey interview, a pharmaceutical company executive defined Thought Leader Select’s value in this manner: “We always think we know our physician key opinion leaders in a given therapeutic area. Your company provides immense value not only in validating our KOLs with thorough, objective information on their skills and experiences, but also in pointing out to us that there are other experts out there whom we should be engaging in the development of new medicines.”
A case in point is Thought Leader Select’s recent analysis of a pool of global key opinion leaders in the therapeutic area of infectious diseases for a large, multi-national pharmaceutical company. For the study, the company supplied the names of 32 medical experts they had engaged in Europe and North America and asked Thought Leader Select to profile and compare the skills and experiences of these physicians with those of 23 new thought leaders identified and profiled by Thought Leader Select in those same geographic regions.
The results of the study provided the client company with a better understanding of the skills and experiences of not only their current pool of medical advisors, but those of an expanded pool as well. In the analysis of the new, larger pool of physicians in the areas of development most important to the client, Thought Leader ... read more »
May 27, 2010 ·
Leave a comment
Key opinion leaders (KOLs) are health care leaders who make a high-impact footprint while advancing medical science. Thought Leader Select specializes in delivering objective, validated data on the skills and experiences of KOLs, so that pharmaceutical companies can seek their appropriate advice and guidance in the development of new medicines.
Thought Leader Select measures many areas where KOLs leave their respective marks in the medical community, including conducting clinical research studies, publishing articles in leading journals, and presenting breakthrough knowledge at scientific conferences.
In a recent assessment of 57 infectious disease specialists, Thought Leader Select measured the frequency of these global key opinion leaders’ respective participation in advisory boards for the development of new medicines.
Using keywords to link the KOLs with advisory board participation covering a six-year period, Thought Leader Select found that 37 of the 57 physicians had relevant advisory board experience to assist its client company in the development of new antibiotics. Of the 37 physicians with documented advisory board experience, 20 had served on more than four boards in the last few years.
The top decile for the KOL pool averaged participation in nine or more advisory boards during the period of the study.